Kyverna Therapeutics, Inc. (KYTX)
| Market Cap | 526.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -161.31M |
| Shares Out | 60.53M |
| EPS (ttm) | -3.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 865,371 |
| Open | 8.96 |
| Previous Close | 8.99 |
| Day's Range | 8.58 - 9.23 |
| 52-Week Range | 1.92 - 13.67 |
| Beta | 2.64 |
| Analysts | Strong Buy |
| Price Target | 20.75 (+138.51%) |
| Earnings Date | May 12, 2026 |
About KYTX
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for KYTX stock is "Strong Buy." The 12-month stock price target is $20.75, which is an increase of 138.51% from the latest price.
News
Kyverna Therapeutics Transcript: Status update
Miv-cel showed rapid, durable, and clinically meaningful improvements in SPS and gMG, with a strong safety profile and the potential to eliminate chronic immunotherapies. Launch strategy targets high-need SPS patients at specialized centers, with robust physician support and regulatory momentum.
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for pati...
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026
Kyverna Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Transformative pivotal data for miv-cel in stiff person syndrome showed disease reversal and strong safety, with BLA filing and launch targeted for this year. Pipeline expansion includes myasthenia gravis and progressive MS, supported by robust manufacturing and a focused commercial strategy.
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
Late-breaking oral presentation to feature primary analysis from KYSA-8 registrational trial in stiff person syndrome (SPS)
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
EMERYVILLE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune dise...
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune disea...
Kyverna Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Transformative clinical results in SPS and MG have set the stage for a first-in-class CAR-T launch, with strong regulatory alignment, robust financials, and validated manufacturing. Expansion into additional autoimmune indications and next-generation platforms is underway.
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 First patient en...
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients w...
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patient...
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Tuesday.
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patient...
Kyverna Therapeutics Transcript: Study Result
The phase II KYSA-8 trial of miv-cel in stiff person syndrome met all primary and secondary endpoints, showing rapid, durable, and clinically meaningful improvements in mobility and disability, with a favorable safety profile. These results support a BLA submission in 2026 and position miv-cel as a potential first-in-class therapy for SPS.
Kyverna's cell therapy meets main goal of mid-stage study
Kyverna Therapeutics said on Monday its experimental cell therapy for treating patients with a rare movement disorder met the main goal of a mid-stage study, sending its shares surging 20% in premarke...
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – – Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET –
Kyverna Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Pivotal clinical progress in CAR T therapy for autoimmune diseases is highlighted, with KYV-101 showing strong efficacy and safety in SPS and MG. First-mover advantage, robust financials, and a growing pipeline position the company for leadership in this space.
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guidance of first half 2026; BLA submission anticipated in 1H 2026
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
EMERYVILLE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients w...
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
Initial funding of $25 million from the first of four tranches Facility strengthens Kyverna's financial flexibility, further supporting advancement of its late-stage indications in generalized myasth...
Kyverna Therapeutics Transcript: Study Update
Interim phase II data for KYV-101 in gMG showed rapid, robust, and sustained efficacy, with all patients achieving clinically meaningful responses and most discontinuing immunosuppressants. The safety profile was manageable, and results support advancing to a well-powered phase III trial.